Who
Howard W. Robin
President & CEO
Company insider
Files Form 4 as: President & CEO, Nektar Therapeutics; CEO & President, Sirna Therapeutics.
In numbers
- Trades disclosed
- 317
- Buys
- 1
- Sells
- 92
- Bought
- $113K
- Sold
- $100.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 21 Feb 2006
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K418 at $71.98 | filing |
| 18 Aug 2026filed 20 Aug 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K418 at $71.98 | filing |
| 24 Jul 2026filed 24 Jul 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,200 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,200 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $334K5,500 at $60.81 | filing |
| 17 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $277K4,500 at $61.65 | filing |
| 17 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $334K5,500 at $60.81 | filing |
| 17 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $277K4,500 at $61.65 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $318K5,303 at $59.97 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $285K4,697 at $60.71 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $318K5,303 at $59.97 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $285K4,697 at $60.71 | filing |
| 19 May 2026filed 21 May 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K444 at $65.51 | filing |
| 19 May 2026filed 21 May 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K444 at $65.51 | filing |
| 18 Feb 2026filed 20 Feb 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K423 at $73.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K423 at $73.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —86,667 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —21,667 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K2,207 at $54.28 | filing |
| 21 Nov 2025filed 25 Nov 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,170 at $0.00 | filing |
News
Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Howard W. Robin; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.